JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Learn more about:
Related Clinical Trial
Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma by Injection Into the Affected Areas
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
Canakinumab for Pyoderma Gangrenosum
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease